Alzheimer's Disease Instruments Validation Study in Asia

Joan Shen,Qi Shen,Holly Yu,Zhengxin Zhang,Huali Wang,Seong Yoon Kim,Timothy Kwok,Christopher Chen,Shuu-Jiun Wang,Dong Young Lee,Jeffrey Cummings,John Harrison,Jin-Shei Lai,Jennifer Beaumont,David Cella,Ronald S. Black

DOI: https://doi.org/10.1016/j.jalz.2012.05.1466

2012-01-01

Abstract:The Asian Alzheimer's disease (AD) instrument validation study is designed to assess if the major AD instruments developed in western countries are valid and reliable for use among the Asian AD population. The report here is the result of the first interim analysis. This is a multicenter, longitudinal, non-interventional study including five Asian countries/regions. The instruments included ADAS-Cog, DAD, Neuropsychological Test Battery (NTB), CDR, MMSE and Dependence Scale (DS). Study method was previously described in detail (poster 16402, AAICAD 2011). 302 participants (251AD patients, 51 healthy controls) were enrolled for the study. Screening and baseline data were analyzed here. The mean age of participants was 71 years (range: 50-85). Over half of participants were female (57%). Most participants were married (83%) and living with a spouse (71%). 32% of the subjects had at least some college education. The nationality of participants generally aligned with the region of their enrolment. Healthy controls showed better cognitive functioning than AD subjects (P<.05) with magnitude varying across the specific neuropsychological tests. Overall, minimal ceiling effect was found for AD subjects across various tests while ceiling effect was found for health y control for many tests. For AD participants, test-retest reliability was confirmed with ICC > 0.7 for 17 of 19 tests. Non-NTB tests were significantly (P< 0.05) correlated with each other and with NTB component, summary and total scores, supporting convergent and divergent validity. Greater disease severity corresponded to significantly (P< 0.003) poorer performance on nearly every assessment, supporting discriminant validity. ApoE4 was detected in 85 of 210 (40.5%) AD patients and 5 of 36 (13.9%) healthy controls (P=0.002). ApoE4 was detected in 44 (40.7%) with mild AD and 41 (40.2%) with moderate/severe AD. There were no significant differences among ApoE4 carriers and non-carriers on instrument scores. This study is the first to evaluate the psychometric properties of multiple AD instruments in five Asian countries/regions. These promising results support the initial psychometric properties of these instruments, enabling their use in Chinese, Korean, and English-speaking AD population in a psychometrically sound manner. Data collection is on-going to evaluate their responsiveness over time.